SAN DIEGO, Aug. 20, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 ...
Hosted on MSN
Arthrosi gains $153m for development of gout therapy
US-based biotechnology company Arthrosi Therapeutics has completed a series E funding round, amassing $153m which is earmarked to advance the clinical development of its flagship programme, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback